Peter C Gøtzsche Ölümcül İlaçlar Referanslar
BÖLÜM 1
References
1 Tobacco companies expand their epidemic of death. Lancet. 2011; 377: 528.
2 Diethelm PA, Rielle JC, McKee M. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet. 2005; 366: 86–92.
3 Tanne JH. Drug advertisements in US paint a ‘black and white scenario’. BMJ. 2007;
334: 279.
4 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
5 Almashat S, Preston C, Waterman T, et al. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. Public Citizen. 2010 Dec 16.
6 Straarup B. [Good treatment – then hotels are no. 1]. Berlingske Tidende. 2005 Nov 25.
7 Harris G. Drug makers seek to mend their fractured image. New York Times. 2004; July
8 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
BÖLÜM 2
References
1 Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; 2: CD007176.
2 Knaus H. Corporate profile, Ciba Geigy: pushing pills and pesticides. Multinational Monitor. 1993. Available online at: http://multinationalmonitor.org/hyper/issues/1993/04/mm0493_11.html (accessed 10 July 2012).
3 Dunne M, Flood M, Herxheimer A. Clioquinol: availability and instructions for use.
J Antimicrob Chemother. 1976; 2: 21–9.
4 Hansson O. Arzneimittel-Multis und der SMON-Skandal. Berlin: Arzneimittel- Informations-Dienst GmbH; 1979.
5 Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949; 24: 181–97.
6 Pearce N. Adverse Reactions: the fenoterol story. Auckland: Auckland University Press; 2007.
7 Gøtzsche PC. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
8 Michaels D. Doubt is their Product. Oxford: Oxford University Press; 2008.
9 Smith SM, SchroederK, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2008; 1: CD001831.
10 Tomerak AAT, Vyas HHV, Lakhanpaul M, et al. Inhaled beta2-agonists for non- specific chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.
11 Wilkinson EAJ, Hawke CC. Oral zinc for arterial and venous leg ulcers. Cochrane Database Syst Rev. 1998; 4: CD001273 (updated in 2010).
12 Husain SL. Oral zinc sulphate in leg ulcers. Lancet. 1969; 1: 1069–71.
13 Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders:
a double-blind, parallel study in sportsmen. Pharmatherapeutica. 1984; 3: 535–41.
14 Jørgensen FR, Gøtzsche PC, Hein P, et al. [Naproxen (Naprosyn) and mobilization in the treatment of acute ankle sprains]. Ugeskr Læger. 1986; 148: 1266–8.
15 Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999; 354: 1229–33.
16 Gøtzsche PC. Bias in double-blind trials. Dan Med Bull. 1990; 37: 329–36.
17 Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol. 1990; 43: 1313–18.
18 Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull. 1989; 36: 395–9.
19 Lopez BL, Flenders P, Davis-Moon L. Clinically significant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis. Hemoglobin. 2007; 31: 427– 32.
20 Gøtzsche PC. Non-steroidal anti-inflammatory drugs. Clinical Evidence. 2004; 12: 1702–10.
21 Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.
22 Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995. 23 Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal
complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996; 312: 1563–6.
24 Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.
25 Joyce C, Lesser F. Opren deaths kept secret, admits Lilly. New Sci. 1985; 107: 15–16. 26 Cotter J. New restrictions on celecoxib (Celebrex) use and the withdrawal of
valdecoxib (Bextra). CMAJ. 2005; 172: 1299.
BÖLÜM 3
References
1 Available online at: http://en.wikiquote.org/wiki/William_Osler (accessed 30 August 2012).
2 Kelton E. More drug companies to pay billions for fraud, join the ‘dishonor roll’ after Abbott settlement. Forbes. 2012 May 10.
3 PhRMA Code on Interactions with Healthcare Professionals – Signatory Companies.
Available online at: www.phrma.org/sites/default/files/108/signatory_companies_phrma_code_061112.pdf (accessed 25 June 2012).
4 Advertisement for Philip Morris International. Berlingske. 2004 Mar 14.
5 Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.
6 Rockoff JD, Matthews CM. Pfizer settles federal bribery investigation. Wall Street Journal. 2012 Aug 7.
7 Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26.
8 Corporate Crime in the ’90s: the top 100 corporate criminals of the 1990s.
Multinational Monitor. 1999 July/August; 20(7, 8).
9 Barboza D. Tearing down the facade of ‘Vitamins Inc.’. New York Times. 1999 Oct 10. 10 F. Hoffmann-La Roche and BASF Agree to Pay Record Criminal Fines for Participating in
International Vitamin Cartel. US Department of Justice. 1999 May 20. 11 Mathiason N. Blowing the final whistle. The Guardian. 2001 Nov 25.
12 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
13 Bobst EH. Bobst: the autobiography of a pharmaceutical pioneer. New York: David McKay Company; 1973.
14 Bruun K. International drug control and the pharmaceutical industry. In: Cooperstock R, editor. Social Aspects of the Medical Use of Psychotropic Drugs. Toronto: Addiction Research Foundation of Ontario. Papers presented at the International Symposium on Alcohol and Drug Research; 1973. Department of National Health and Welfare; 1974.
15 Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re- uptake inhibitors. Addiction. 2012; 107: 900–8.
16 Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.
17 House of Commons Health Committee. The Influence of the Pharmaceutical Industry.
Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
18 Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
19 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
20 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
21 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001. 22 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
23 Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped.
BMJ. 2012; 345: e8462.
24 Gøtzsche PC. Corporate crime in the pharmaceutical industry is common, serious and repetitive. Available online at: www.cochrane.dk/research/corporatecrime/Corporate-crime-long-version.pdf (accessed 20 December 2012).
25 Pfizer agrees record fraud fine. BBC News. 2009 Sept 2.
26 Tanne JH. Pfizer pays record fine for off-label promotion of four drugs. BMJ. 2009;
339: b3657.
27 Evans D. Big pharma’s crime spree. Bloomberg Markets. 2009 Dec: 72–86.
28 United States Department of Justice. Novartis Pharmaceuticals Corp. to Pay More than
$420 million to Resolve Off-Label Promotion and Kickback Allegations. 2010 Sept 30.
29 SourceWatch. Sanofi-Aventis. 2011 Jan 23. Available online at:
www.sourcewatch.org/index.php?title=Sanofi-Aventis (accessed 19 June 2012).
30 Aventis to pay $95 million to settle fraud charge. AFP. 2009 May 28.
31 Rabiner S. Glaxo $3B fine largest healthcare fraud settlement in history? FindLaw.
2011 Nov 10.
32 United States Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 billion to Resolve Fraud Allegations and Failure to Report Safety Data. 2012 July 2.
33 Thomas K, Schmidt MS. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.
34 Wilson D. Ex-Glaxo executive is charged in drug fraud. New York Times. 2010 Nov 9. 35 Khan H, Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case.ABC News. 2010 April 27.
36 Tanne JH. AstraZeneca pays $520m fine for off-label marketing. BMJ. 2010; 340: c2380.
37 Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ. 2009;
339: b5164.
38 Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009; 339: b5387.
39 Cohen D, Carter P. WHO and the pandemic flu ‘conspiracies’. BMJ. 2012; 340: c2912. 40 Willman D. Relenza: official asks if one day less of flu is worth it. Los Angeles Times.
2000 Dec 20.
41 Epstein H. Flu warning: beware the drug companies! New York Review of Books. 2001 Apr 11.
42 Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012; 1: CD008965.
43 Rennie D. Guarding the guardians: a conference on editorial peer review. JAMA.
1986; 256: 2391–2.
44 Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012; 9: e1001201.
45 O’Dowd A. Response to swine flu was ‘unjustified’, says Council of Europe. BMJ.
2012; 340: c3033.
46 Gøtzsche PC. European governments should sue Roche and prescribers should boycott its drugs. BMJ. 2012; 345: e7689.
47 Cohen D. Search for evidence goes on. BMJ. 2012; 344: e458.
48 Ark. judge fines Johnson & Johnson more than $1.1B in Risperdal case. CBS/AP.
2012 April 11.
49 Harris G. Research center tied to drug company. New York Times. 2008 Nov 25. 50 Kelton E. J&J needs a cure: new CEO allegedly had links to fraud. Forbes. 2012 17
April.
51 Silverman E. Merck to pay $670 million over Medicaid fraud. Pharmalot. 2008 Feb 7. 52 Reuters. The largest pharma fraud whistleblower case in U.S. history totaling
$1.4 billion. 2009 Jan 15.
53 Anonymous. Abbott Labs to pay $1.5 billion more for Medicaid fraud. 2012 May 8.
Available online at: http://somd.com/news/headlines/2012/15451.shtml (accessed 19 June 2012).
54 Roehr B. Abbott pays $1.6bn for promoting off label use of valproic acid. BMJ. 2012;
344: e3343.
55 Barnes K. Sanofi slammed by FDA over failure to act on Ketek fraud. Outsourcing.2007 Oct 25.
56 Ross DB. The FDA and the case of Ketek. N Engl J Med. 2007; 356: 1601–4.
57 Soreth J, Cox E, Kweder S, et al. Ketek – the FDA perspective. N Engl J Med. 2007;
356: 1675–6.
58 Ketek Official FDA information, side effects and uses. Available online at: www.drugs.com/pro/ketek.html (accessed 18 Nov 2012).
59 Russell J. Johnson & Johnson feels pain of $75m bribery fines. The Telegraph. 2011 9 April.
60 Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet.
Available online at: www.conspiracyplanet.com/channel.cfm? channelid=55&contentid=4181&page=2 (accessed 28 June 2012).
61 Clinard MB, Yeager PC. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
62 Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
63 Lane C. Bad medicine: GlaxoSmithKline’s fraud and gross negligence. Psychology Today. 2011 Jan 7.
64 Silverman E. Glaxo to pay $750M for manufacturing fraud. Pharmalot. 2010 Oct 26. 65 Wikipedia. GlaxoSmithKline. Available online at:
http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).
66 Carpenter G. Italian doctors face charges over GSK incentive scheme. Over 4000 doctors are alleged to have received cash, gifts, and prizes to encourage them to prescribe GSK products. Lancet. 2004; 363: 1873.
67 Company news; drug maker agrees to pay $175 million in lawsuit. New York Times.
2004 Feb 7.
68 Prescription generics & patent management. Strategies in the Pharmaceutical Industry 2004. 2004 Nov 29.
69 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
70 Jack A. Legal tactics to delay launch of generic drugs cost Europe €3bn. BMJ. 2008;
337: 1311.
71 Tanne JH. Bristol-Myers Squibb made to pay $515 m to settle US law suits. BMJ.
2007; 335: 742–3.
72 Anonymous. Bristol-Myers will settle antitrust charges by U.S. New York Times. 2003 March 8.
73 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
74 European Commission. Antitrust: Commission fines Lundbeck and other pharma
75 companies for delaying market entry of generic medicines. Press release. 2013 June 19. 75 Abelson R. Whistle-blower suit says device maker generously rewards doctors. New
York Times. 2006 Jan 24.
76 Poses RM. Medtronic settles, yet again. Blog post. Health Care Renewal. 2011 Dec 15. Available online at: http://hcrenewal.blogspot.co.nz/2011/12/medtronic-settles-yet- again.html (accessed 10 July 2013).
77 Tanne JH. US companies are fined for payments to surgeons. BMJ. 2007; 335: 1065. 78 Harris G, Pear R. Drug maker’s efforts to compete in lucrative insulin market are
under scrutiny. New York Times. 2006 Jan 28.
79 Abelson R. How Schering manipulated drug prices and Medicaid. New York Times.
2004 July 31.
80 Harris G. Drug makers settled 7 suits by whistle-blowers, group says. New York Times.
2003 Nov 6.
81 OxyContin’s deception costs firm $634M. CBS News. 2007 May 10.
82 Zee A van. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Publ Health. 2009; 99: 221–7.
83 Wordsworth M. Deadly epidemic fears over common painkiller. ABC News. 2012 Nov 14.
84 Kendall B. Court backs crackdown on drug officials. Wall Street Journal. 2010 July 27. 85 Tansey B. Huge penalty in drug fraud: Pfizer settles felony case in Neurontin off-
label promotion. San Francisco Chronicle. 2004 May 14.
86 Collier J. Big pharma and the UK government. Lancet. 2006; 367: 97–8.
87 Ferner RE. The influence of big pharma. BMJ. 2005; 330: 857–8.
88 Smith R. Curbing the influence of the drug industry: a British view. PLoS Med. 2005;
2: e241.
89 Moynihan R. Officials reject claims of drug industry’s influence. BMJ. 2004; 329: 641. 90 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
91 Free Online Law Dictionary. Organized crime. Available online at: http://legal- dictionary. thefreedictionary.com/Organized+Crime (accessed 2 December 2012).
92 Peter Rost. Blog. Available online at: http://peterrost.blogspot.dk (accessed 26 June 2012).
93 Almashat S, Preston C, Waterman T, et al. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. Public Citizen. 2010 Dec 16.
94 Almashat S, Wolfe S. Pharmaceutical industry criminal and civil penalties: an update.
Public Citizen. 2012 Sept 27.
BÖLÜM 4
References
1 Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009; 3: CD007954.
2 Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344: 1594–602.
3 Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions.
Cochrane Database Syst Rev. 2010; 1: CD003974.
4 Blumenthal DS, Burke R, Shapiro AK. The validity of ‘identical matching placebos’.
Arch Gen Psychiatry. 1974; 31: 214–15.
5 Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. BMJ. 2006; 333: 231–4.
6 Hróbjartsson A, Thomsen AS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012; 344: e1119.
7 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
8 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
9 Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.
10 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–9.
11 Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008; 2: CD000165.
12 Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; 1: CD004816.
13 Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012; 172:1180–2.
14 Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004; 1: CD003012.
15 Boyd R. A view from the man in the seat opposite. BMJ. 1998; 317: 410.
16 Villesen K, Rottbøll E. [Drug industry blocks free research]. Information. 2012 Feb 3. 17 The tightening grip of big pharma. Lancet. 2001; 357: 1141.
BÖLÜM 5
References
1 Boseley S. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian. 2002 Feb 7.
2 Vandenbroucke JP. Without new rules for industry-sponsored research, science will cease to exist. BMJ. 2005 Dec 14. McHenry L. Biomedical research and corporate interests: a question of academic freedom. Mens Sana Monographs. 2008 Jan 1.
3 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
4 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
5 Medawar C, Hardon A. Medicines out of Control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.
6 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
7 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001–15.
8 Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med. 2007; 357: 28–38.
9 Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045–57.
10 Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials – common patterns in TRITON, RECORD, and PLATO? Thromb Haemost. 2012; 108: 412–14.
11 Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. JAMA. 2001; 286: 1232–4.
12 Nordic Medical Research Councils’ HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ. 1992; 304: 13–17.
13 Gerstoft J, Melander H, Bruun JN, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. Scand J Infect Dis. 1997; 29: 121–8.
14 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006; 295: 1645–6.
15 Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010; 303: 1180–7.
16 Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical- trial agreements between medical schools and industry sponsors. N Engl J Med. 2002; 347: 1335–41.
17 Mello MM, Clarridge BR, Studdert DM. Academic medical centers standards for clinical-trial agreements with industry. N Engl J Med. 2005; 352: 2202–10.
18 Meier B. Contracts keep drug research out of reach. New York Times. 2004 Nov 29. 20 Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med. 2005; 352:2160–2.
21 Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003; 289: 454–65.
22 Statistics from the EudraCT database. EMEA/363785/2005.
23 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
24 Department of Health and Human Services, Office of Inspector General. Recruiting Human Subjects: pressures in industry-sponsored clinical research. June 2000, OEI-01-97- 00195 (accessed 18 February 2008).
25 Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.
26 Werkö L. [It is always about the life] [Swedish]. Helsingborg: AB Boktryck; 2000.
27 Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.
28 Gagnon M-A. The Nature of Capital in the Knowledge-Based Economy: the case of the global pharmaceutical industry [dissertation]. Toronto: York University; May 2009.
29 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
30 Elliott C. The drug pushers. The Atlantic Monthly. 2006 April.
31 Marcovitch H. Editors, publishers, impact factors, and reprint income. PLoS Med.
2010; 7: e1000355.
32 Bodenheimer T. Uneasy alliance – clinical investigators and the pharmaceutical industry. N Engl J Med. 2000; 342: 1539–44.
33 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy.
2007 July: 991–1012.
34 Kesselheim AS, Robertson CT, Myers JA, et al. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012; 367: 1119–27.
35 Drazen JM. Believe the data. N Engl J Med. 2012; 367: 1152–3.
36 Sun X, Briel M, Busse JW, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ. 2011; 342: d1569.
37 Lenzer J. NIH secrets. The New Republic. 2006 Oct 10.
38 Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990; 322: 1405–11.
39 Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004; 364: 1321–8.Lenzer J, Brownlee S. An untold story? BMJ. 2008; 336: 532–4.
40 Mintzberg H. Patent nonsense: evidence tells of an industry out of social control.
CMAJ. 2006; 175: 374.
BÖLÜM 6
References
1 Smith R. A ripping yarn of editorial misconduct. BMJ. Group blogs. 2008 Oct 21.
2 Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006. 3 Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis –
learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8– 24.
4 Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication. February 2006. International Committee of Medical Journal Editors website. Available online at: www.icmje.org (accessed 23 January 2006).
5 Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005; 2: e138.
6 Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1(1): e6.
7 Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.
8 Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ.
2006; 332: 1444–7.
9 Lundh A, Barbateskovic M, Hróbjartsson A, et al. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010; 7: e1000354.
10 Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med. 2002; 346: 1901–2.
11 Kassirer J. What the New England Journal of Medicine did. BMJ. 2011; 343: d5665. 12 Horton R. The dawn of McScience. New York Rev Books. 2004; 51: 7–9.
13 Eaton L. Editor claims drug companies have a ‘parasitic’ relationship with journals.
BMJ. 2005; 330: 9.
14 Handel AE, Patel SV, Pakpoor J, et al. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012; 344: e4212.
15 Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344: 1594–602.
16 Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2006; 1: CD004707.
17 Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346: 225–34.
18 Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408–15.Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006, 7: 3.
19 Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.
20 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775–89.
21 Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008; 31: 927–33.
22 Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992; 327: 1135–40.
23 Cho MK, Bero LA. The quality of drug studies published in symposium proceedings.
Ann Intern Med. 1996; 124: 485–9.
24 Lenzer J. Editor earned over $20m in royalties and $2m in fees from device manufacturer. BMJ. 2010; 340: c495.
25 Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011; 11: 471–91.
26 Abbasi K. Editor’s choice: a tough nut to crack. BMJ. 2005; 330: Jan 29.
27 Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
BÖLÜM 7
References
1 Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.
2 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
3 Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
4 Wilmshurst P. Academia and industry. Lancet. 2000; 356: 338–44.
5 Steinman MA, Bero LA, Chren MM, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145: 284–93.
6 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
7 Transparency International. Global Corruption Report 2006. Available online at: www.transparency.org/publications/gcr (accessed 8 February 2008).
8 House of Commons Health Committee. The Influence of the Pharmaceutical Industry.
Fourth Report of Session 2004–05. 2005. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
9 Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
10 Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA. 2000; 283: 373–80.
11 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
12 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
13 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
14 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
15 Gale EA. Conflicts of interest in guideline panel members. BMJ. 2011; 343: d5728. 16 Boseley S. Drug firms using backdoor tactics to boost sales, report reveals. The Guardian. 2011 Sept 23.
17 Lenzer J. Whistleblower removed from job for talking to the press. BMJ. 2004; 328: 1153.
18 Elliott C. The drug pushers. The Atlantic Monthly. 2006 April.
19 Palo J. Why did my colleagues turn to crime? BMJ. 2004; 328: 1083.
20 Applegate WB, Furberg CD, Byington RP, et al. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA. 1997; 277: 297.
21 Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
22 Elkjær B, Rebouh D, Jensen J, et al. [See if your doctor is in industry’s pocket]. Ekstra Bladet. 2010 June 24.
23 Editorial. [The greedy doctors]. Ekstra Bladet. 2010 June 24.
BÖLÜM 8
References
1 Danish National Board of Health. [List of permissions for physicians and dentists].
Available online at: http://ext.laegemiddelstyrelsen.dk/tilladelselaegertandlaeger/tilladelse_laeger_tandlae vis=hele (accessed November 2010).
2 Gagnon M-A. Corporate influence over clinical research: considering the alternatives.
Rev Prescrire. 2012; 32: 311–14.
3 Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
4 Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012; 2: CD008615.
5 Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet. 2009: 374: 1501–2.
6 Tfelt-Hansen P, Hauchildt Juhl H. [Treatment of migraine with triptans – a commented foreign health technology assessment]. Copenhagen: Sundhedsstyrelsen; 2008.
7 Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry. 2010. DOI 10.1007/s11673-010-9208-8.
8 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
9 Sox HC, Rennie D. Seeding trials: just say ‘no’. Ann Intern Med. 2008; 149: 279–80. 10 Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
11 Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA. 2006; 295: 2759–64.
12 Psaty BM, Rennie D. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA. 2006; 295: 2787–90.
13 Nielsen HL. Linking Healthcare: an inquiry into the changing performances of web-based technology for asthma monitoring [PhD dissertation]. Copenhagen Business School, Department of Organization and Industrial Sociology; 2005.
14 Jackson T. Are you being duped? BMJ. 2001; 322: 1312.
15 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
16 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
17 Henry D, Doran E, Kerridge I, et al. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. Arch Intern Med. 2005; 165: 2493–6.
18 Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.
19 Abelson R. Whistle-blower suit says device maker generously rewards doctors. New York Times. 2006 Jan 24.
20 Thompson M, Heneghan C. BMJ open data campaign: time to move the debate forward. BMJ 2012; 345: 25.
21 Godlee F. Open letter to Roche about oseltamivir trial data. BMJ. 2012; 345: e7305. 22 Moore J. Medical device payments to doctors draw scrutiny. Star Tribune. 2008 Sept 8.
23 Lenzer J. Doctor’s group files legal charges against nine French doctors over competing interests. BMJ. 2009; 338: 1408.
24 Moynihan R. Key opinion leaders, independent experts of drug representatives in disguise? BMJ. 2008; 336: 1402–3.
25 Steinman MA, Bero LA, Chren MM, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145: 284–93.
26 [Guidelines for the requirement of physicians and dentists to get permission to be connected to a drug company]. Copenhagen: Sundhedsstyrelsen; 2011 June 28.
27 Boseley S. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian. 2002 Feb 7.
28 Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
29 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
30 Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.
31 Bowman MA. The impact of drug company funding on the content of continuing medical education. Möbius. 1986; 6: 66–9.
32 Moynihan R. Doctors’ education: the invisible influence of drug company sponsorship. BMJ. 2008; 336: 416–17.
33 Burton B, Rowell A. Disease Mongering. SpinWatch. 2003. Available online at: www.spinwatch.org/component/content/article/47-pharma-industry/29-disease- mongering (accessed 11 November 2012).
34 Key Opinion Leaders Europe. Conference announcement. SMI. 2009 June 15–16.
35 Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).
36 Wilmshurst P. Academia and industry. Lancet. 2000; 356: 338–44.
37 Carlat D. Dr drug rep. New York Times. 2007 Nov 25.
38 Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007; 4: e150.
39 Blum A, Solberg E, Wolinsky H. The Surgeon General’s report on smoking and health 40 years later: still wandering in the desert. Lancet. 2004; 363: 97–8.
40 Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288: 321–33.
41 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
42 Clark J. A hot flush for big pharma. BMJ. 2003; 327: 400.
43 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
44 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
45 Wise J. European drug agency criticises Roche for failing to report adverse reactions and patient deaths. BMJ. 2012; 344: e4344.
BÖLÜM 9
References
1 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
2 Gøtzsche PC. Bias in double-blind trials (thesis). Dan Med Bull. 1990; 37: 329–36.
3 Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials. 1989; 10: 31–56 (amendment: 356).
4 Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Tech Assessm Health Care. 1996; 12: 209–37.
5 Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002; 190: 583–92.
6 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
7 McGauran N, Wieseler B, Kreis J, et al. Reporting bias in medical research – a narrative review. Trials. 2010; 11: 37.
8 Boutron I, Dutton S, Ravaud P, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010; 303: 2058–64.
9 Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. Dan Med Bull. 1989; 36: 493–5.
10 Gøtzsche PC. Patients’ preference in indomethacin trials: an overview. Lancet. 1989;
i: 88–91.
11 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
12 Bero L, Oostvogel F, Bacchetti P, et al. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007; 4: e184.
13 Kelley C, Helfand M, Good C, et al. Drug class review. Hydroxymehylglutaryl- coenzyme A reductase inhibitors (statins). 2002 Dec. Available online at: www.pbm.va.gov/reviews/hmgstatins04-09-03.pdf (accessed 11 November 2012).
14 Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome.
Cochrane Database Syst Rev. 2012; 12: MR000033.
15 Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006; 163: 185–94.
16 Moffatt B, Elliott C. Ghost marketing. Perspect Biol Med. 2007; 50: 18–31.
17 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy.
2007 July: 991–1012.
18 Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003; 183: 22–7.
19 Sismondo S, Nicholson SH. Publication planning 101: a report. J Pharm Pharmaceut Sci. 2009; 12: 273–9.
20 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. Ghost authorship in industry- initiated randomised trials. PLoS Med. 2007; 4: e19.Yank V, Rennie D. Disclosure of researcher contributions: a study of original research articles in The Lancet. Ann Intern Med. 1999; 130: 661–70.
21 Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. 1998; 280: 222– 4.
22 Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004; 34: 219–45.
23 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
24 Zuger A. How tightly do ties between doctor and drug company bind? New York Times. 2004 June 27.
25 Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73: 4–8.
26 Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam Pract. 2003; 20: 61–8.
27 Henry D, Doran E, Kerridge I, et al. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. Arch Intern Med. 2005; 165: 2493–6.
28 Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742–50.
29 Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5: e1.
30 Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
31 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
32 Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA. 2000; 283: 373–80.
33 Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
34 Steinman MA, Harper GM, Chren MM, et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.
35 Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885–90. 37 Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug
companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
38 Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992; 102: 270–3.
39 Morgan SG, Bassett KL, Wright JM, et al. ‘Breakthrough’ drugs and growth inexpenditure on prescription drugs in Canada. BMJ. 2005; 331: 815–6.
40 Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.
41 Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006; 7: 3.
42 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97.
43 Lieberman JA, Stroup TS, McEvoy, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209–23.
44 Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079–87.
45 Woo WWK, Man S-Y, Lam PKW, et al. Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med. 2005; 46: 352–61.
46 Villanueva P, Peiró S, Librero J, et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003; 361: 27–32.
47 Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.
48 Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006; 333: 782–5.
49 Malhotra D. Pharmaceutical lies. BMJ. 2006 Oct 28.
50 Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010; 7: e1000352.
51 Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.
52 Bowman MA. The impact of drug company funding on the content of continuing medical education. Möbius. 1986; 6: 66–9.
53 Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).
54 Tramèr MR, Reynolds DJ, Moore RA, et al. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997; 315: 635–40.
55 Aspinall RL, Goodman NW. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995; 311: 844–6.
56 Carlisle J, Stevenson CA. Drugs for preventing postoperative nausea and vomiting.
Cochrane Database Syst Rev. 2006; 3: CD004125.
57 Carlisle JB. A meta-analysis of prevention of postoperative nausea and vomiting: randomised controlled trials by Fujii et al. compared with other authors. Anaesthesia. 2012; 67: 1076–90.
58 Does anesthesiology have a problem? Final version of report suggests Fujii will take retraction record, with 172. Retraction Watch. 2012 July 3.
59 Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.
60 Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians’ relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351: 1891–900.
61 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
62 Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006. 63 Heissel A. [‘The bomb’ has been defused]. Dagens Medicin. 2011 Feb 4.
64 Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010; 62: 2852–63.
65 Tanne JH. FDA approves prostate cancer ‘vaccine’ treatment. BMJ. 2012; 340: 998. 66 Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in
patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–23.
67 Andersen NV. [Drug with trivial effect]. Politiken. 2012 Feb 5.
68 Rasmussen LI. [‘How can Henrik Dibbern believe that I have interests in the company?’] Ugeskr Læger. 2012; 174: 248–9.
69 Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.
70 Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high- income countries. Lancet Oncol. 2011; 12: 933–80.
71 Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2010; 7: CD007851.
72 Jensen JH, Korsgaard P. [We would drop chemotherapy and enjoy life]. Ekstra Bladet. 2012 March 16.
73 Dreier J. [Chemotherapy or not?]. Danish Cancer Society. 2012 March 19.
74 Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990; 300: 1458–60.
75 Watts G. Why the exclusion of older people from clinical research must stop. BMJ.
2012; 344: e3445.
76 Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733–42.
77 Lenzer J. Spin doctors soft pedal data on antihypertensives. BMJ. 2003; 326: 170. 78 Järhult B, Lindahl S-O. [Doxazosin and heart failure: trustworthy information for patients’ sake]. Läkartidningen. 2003; 48: 4011–12.
79 Fretheim A, Aaserud M, Oxman AD. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Services Research. 2003; 3: 18.
80 Drachmann H, Andersen NV. [Millions to spare on drugs]. Politiken. 2003 Dec 27. 81 Hagerup A. [Focus: drugs]. Ugeskr Læger. 2009; 171: 203–5.
82 Lindberg M. [Interesting statements by Hans Ibsen and Novartis related to new rules for reimbursement of drugs]. Ugeskr Læger. 2010; 172: 2476.
83 Ebdrup N. [Cheap antihypertensives equally good as expensive ones]. Videnskab.dk.
2012 April 13.
84 Gøtzsche PC. Reply. Ugeskr Læger. 2011; 173: 599.
85 Boseley S. Concern over cancer group’s link to drug firm. The Guardian. 2006 Oct 18. 86 Coleman M. New drugs and survival: does the Karolinska report make sense? Cancer
World. 2006 Sept–Oct: 26–35.
87 Gøtzsche PC. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
88 US Department of Justice. Danish pharmaceutical Novo Nordisk to pay $25 million to resolve allegations of off-label promotion of Novoseven. 2011 June 10.
89 Christenson S, Finley D. Drug firm’s wooing made whistleblower suspicious: Fort Sam doctor was early backer of medication to halt bleeding. San Antonio Express. 2011 June 26.
90 Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59: 8–18.
91 Webert KE, Blajchman MA. Randomized trials in patients with blunt and penetrating trauma. J Trauma. 2006; 60: 242–3.
92 Andersen NV, Ellesøe M. [Novo blockbuster buried]. Mandag Morgen. 2008; 27: 9–13.
93 Tedesco J. Military medicine scheme is alleged: S.A. nonprofit tied to alleged scam to influence decisions by doctors. San Antonio Express. 2011 July 20.
94 Mogensen T. [Who is guarding the guardian?]. Ugeskr Læger. 2008; 170: 3076.
BÖLÜM 10
References
1 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
2 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
3 Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.
4 Bailey RS. FDA corruption charges letter verified. The Los Angeles Post. 2012 April 8. 5 Tanne JH. Investigators to review conflicts of interest at NIH. BMJ. 2007; 334: 767. 6 Tanne JH. Former FDA head is fined $90 000 for failing to disclose conflicts of interest. BMJ. 2007; 334: 492.
7 Andersen NA, Drachmann H. [Psychiatrist gets millions]. Politiken. 2003 Dec 5.
8 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
9 Blowing the whistle on the FDA: an interview with David Graham. Multinational Monitor 2004; 25(12).
10 Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329: 1308.
11 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
12 Ross DB. The FDA and the case of Ketek. N Engl J Med. 2007; 356: 1601–4.
13 Baciu A, Stratton K, Burke SP, eds. The Future of Drug Safety: promoting and protecting the health of the public. Washington, DC: National Academies Press; 2006.
14 Smith SW. Sidelining safety – the FDA’s inadequate response to the IOM. N Engl J Med. 2007; 357: 960–3.
15 Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
16 Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995. 17 House of Commons Health Committee. The Influence of the Pharmaceutical Industry.
Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
18 Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006; 296: 1653–6.
19 Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.
20 Garattini S. Confidentiality. Lancet. 2003; 362: 1078–9.
21 Union of Concerned Scientists. FDA Scientists Pressured to Exclude, Alter Findings; scientists fear retaliation for voicing safety concerns. 2006 July 20.
22 Psaty BM, Burke SP. Institute of Medicine on drug safety. N Engl J Med. 2006; 355: 1753–5.
23 Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211. 24 Strom BL. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.
25 Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
26 United States General Accounting Office. Food and Drug Administration: effect of user fees on drug approval times, withdrawals, and other agency activities. Sept 2002.
27 Reuters. Danish drugmaker Lundbeck A/S and Japanese partner Takeda Pharmaceutical Co have submitted a new antidepressant for regulatory approval in the United States. 2012 Oct 2.
28 Avorn J, Shrank W. Highlights and a hidden hazard – the FDA’s new labeling regulations. N Engl J Med. 2006; 354: 2409–11.
29 Letter from FDA scientists to President Barrack Obama. 2009 Apr 2. Available online at: http://gaia-health.com/articles201/000201-letter.pdf (accessed 11 Nov 2012).
30 Lichtblau E, Shane S. Vast FDA effort tracked e-mails of its scientists. New York Times.
2012 July 14.
31 Rosenberg M. Former FDA reviewer speaks out about intimidation, retaliation and marginalizing of safety. Truthout. 2012 July 29.
32 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
33 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
34 Sibbison JB. USA: dirty work in the drug industry. Lancet. 1991; 337: 227. 35 Wikipedia. Duilio Poggiolini. Available online at:
http://en.wikipedia.org/wiki/Duilio_Poggiolini (accessed 10 November 2012).
36 Abbott A. Italian health sector in disarray following more scandals. Nature. 1993;
364: 663.
37 Medawar C, Hardon A. Medicines out of control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.
38 Day M. Italian police arrest drug officials over alleged falsification of data. BMJ.
2008; 336: 1208–9.
39 Pfizer memoranda, 24 and 26 April 1989.
40 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
41 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
42 Ismail M. Drug Lobby Second to None: how the pharmaceutical industry gets its way in Washington. The Center for Public Integrity. 2005 July 7.
43 Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
44 Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency.BMJ. 2011; 342: d2686.
45 Anonymous. FDA more transparent than EMEA. Prescrire International. 2002; 11: 98. 46 Garattini S, Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–
5.
47 Kranish M. Drug industry costs doctor top FDA post. Boston Globe. 2002 May 27. 48 Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley:
University of California Press; 2005.
49 McClellan MB. Speech before First International Colloquium on Generic Medicine.
Available online at: www.fda.gov/oc/speeches/2003/genericdrug0925.html (accessed 18 February 2008).
50 Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008; 358: 1354–61.
51 Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.
52 Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007; 167: 1752–9.
53 Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012 Oct 8: 1–2.
54 Avorn J. Paying for drug approvals – who’s using whom? N Engl J Med. 2007; 356: 1697–700.
55 Psaty BM, Korn D. Congress responds to the IOM drug safety report – in full. JAMA.
2007; 298: 2185–7.
56 Harris G, Halbfinger DM. FDA reveals it fell to a push by lawmakers. New York Times. 2009 Sept 25.
57 Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009; 302: 2679–85.
58 Van Brabandt H, Neyt M, Hulstaert F. Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ. 2012; 345: e4710.
59 Collier J. Big pharma and the UK government. Lancet. 2006; 367: 97–8.
60 Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med. 2008; 5: e191.
61 European Commission. Strategy to Better Protect Public Health by Strengthening and Rationalising EU Pharmacovigilance. 2007 Dec 5.
62 HAI Europe. Pharmacovigilance in Europe and Patient Safety: no to deregulation. Press release. 2008 Feb 1.
63 Larsen H, Nyborg S. [The drug industry asks for control]. Politiken. 2006 Mar 5. 64 [Committee on Scientific Dishonesty tamed]. Ugeskr Læger. 2005; 167: 3476–7.
65 Greene JA, Choudhry NK, Kesselheim AS, et al. Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. JAMA. 2012; 308: 973–5.
66 Welch HG. Should I be Tested for Cancer? Maybe not and here’s why. Berkeley: University of California Press; 2004.
67 Welch HG, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston, MA: Beacon Press; 2011.
68 Andersen NV. [Drug giant uses American pressure in Danish drug case]. Politiken.
2004 Aug 31.
69 Amendment to the Federal Food, Drug and Cosmetic Act. Washington, DC: 4 Jan, 2007. Available online at: www.fda.gov/oc/initiatives/HR3580.pdf (accessed 8 July 2008).
70 Moore TJ, Furberg CD. The safety risks of innovation: the FDA’s Expedited Drug Development Pathway. JAMA. 2012; 308: 869–70.
71 Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012; 1: CD008965.
72 Meier B. Contracts keep drug research out of reach. New York Times. 2004 Nov 29. 73 Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study. Lancet.2005; 366: 1261–2.
74 Rickard KA. Misleading data analyses in salmeterol (SMART) study – GlaxoSmithKline’s reply. Lancet. 2005; 366: 1262.
75 Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993; 306: 1034–7.
76 Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006; 144: 904–12.
77 FDA Drug Safety Communication: new safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2010 Feb 18. Available online at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandPro (accessed 8 October 2012).
78 Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129: 15–26.
79 Curfman GD, Morrissey S, Drazen JM. Products at risk. N Engl J Med. 2010; 363: 1763.
80 Harris G. Pfizer says internal studies show no Celebrex risks. New York Times. 2005 Feb 5.
81 Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.
82 Sherman M, Marchione M. Pfizer: Celebrex raises heart attack risk. ABC News. 2004 Dec 17.
83 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
84 Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. N Engl J Med. 2006; 355: 2169–71.
85 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
86 Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.
87 Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012; 8: CD001831.
88 Tomerak AAT, Vyas HHV, Lakhanpaul M, et al. Inhaled beta2-agonists for non- specific chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.
89 Glintborg D. [Cough medicines for acute respiratory infections, what is the evidence?] Rationel Farmakoterapi. 2003 Jan 4.
90 Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar
– pediatric cough and cold medications. N Engl J Med. 2007; 357: 2321–4.
91 Public Health Advisory: FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. 2011 Feb 23.
92 Parvez L, Vaidya M, Sakhardande A, et al. Evaluation of antitussive agents in man.
Pulm Pharmacol. 1996; 9: 299–308.
93 Goodyear MD, Lemmens T, Sprumont D, et al. Does the FDA have the authority to trump the Declaration of Helsinki? BMJ. 2009; 338: b1559.
94 Wikipedia. Tuskegee syphilis experiment. Available online at: http://en.wikipedia.org/wiki/Tuskegee_syphilis_experiment (accessed 21 January 2010).
95 Boseley S, Smith D. As doctors fought to save lives, Pfizer flew in drug trial team. The Guardian. 2010 Dec 9.
96 Smith D. Pfizer pays out to Nigerian families of meningitis drug trial victims. The Guardian. 2011 Aug 12.
97 Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias.
JAMA. 1990; 263: 1392–5.
98 The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303: 1038–41.
99 Nissen SE. Cardiovascular effects of diabetes drugs: emerging from the dark ages.
Ann Intern Med. 2012; 157: 671–2.
100 Gøtzsche PC, Liberati A, Luca P, et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.
101 Pocock SJ. When to stop a clinical trial. BMJ. 1992; 305: 235–40.
102 Moore TJ. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.
103 Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography.
Cochrane Database Syst Rev. 2013; 6: CD001877.
104 D’Agostino RB Sr. Changing end points in breast-cancer drug approval – the Avastin story. N Engl J Med. 2011; 365: e2.
105 Pollack A. FDA revokes approval of Avastatin for use as breast cancer drug. New York Times. 2011 Nov 18.
106 Lenzer J. FDA is criticised for hinting it may loosen conflict of interest rules. BMJ.
2011; 343: d5070.
107 Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid- altering drugs. JAMA. 2008; 299: 1474–6.
108 Heavey S. FDA warns Pfizer for not reporting side effects. Reuters. 2010 June 10. 109 Wise J. European drug agency criticises Roche for failing to report adverse reactions
and patient deaths. BMJ. 2012; 344: e4344.
110 McCartney M. Statins for all? BMJ. 2012; 345: e6044.
111 Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012; 172: 1180–2.
112 Støvring H, Harmsen CG, Wisløff T, et al. A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality. Eur J Prev Cardiol. 2012 Apr 12.
113 Hampton T. Flawed prescribing practices revealed. JAMA. 2006; 296: 2191–2.
114 Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000; 284: 3036–9.
115 Kingston A. A national embarrassment. Maclean’s Magazine. 2012 Oct 17.
116 Kragh A. [Two of three people in nursing homes are in treatment with at least ten drugs]. Läkartidningen. 2004; 101: 994–9.
117 Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010; 170: 1648–54.
118 Mann H. Beware of polypharmacy in the elderly. BMJ. 2009 March 8. Available online at: www.bmj.com/cgi/eletters/338/mar03_2/b873 (accessed 12 March 2009).
119 Moynihan R. Is your mum on drugs? BMJ. 2011; 343: d5184.
120 Goodwin JS. Geriatrics and the limits of modern medicine. N Engl J Med. 1999; 340: 1283–5.
11
References
1 Vedantam S. Antidepressant makers withhold data on children. Washington Post. 2004 Jan 29.
2 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
3 Melander H. [Selective reporting – greater problem than selective publishing?]
Läkartidningen. 2005; 102: 224–5.
4 Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252–60.
5 Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008; 5: e217.
6 Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.
7 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
8 Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med. 2006; 99: 337–41.
9 Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007; 2: MR000005. MacLean CH, Morton SC, Ofman JJ, et al. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol. 2003; 56: 44–51.
10 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
11 Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990; 263: 1405–8.
12 Danish Association of the Pharmaceutical Industry. [Revised collaborative agreement between the Medical Association and the Danish Association of the Pharmaceutical Industry about clinical trials and non-intervention studies]. 2010 June 1.
13 Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency.
BMJ. 2011; 342: d2686.
14 Wikipedia. Rimonabant. Available online at: http://en.wikipedia.org/wiki/Rimonabant (accessed 17 January 2013).
15 World Medical Association. Declaration of Helsinki – ethical principles for medical research involving human subjects. 2008.
16 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
17 Topol EJ. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med.
2004; 351: 1707–9.
18 Lenzer J. FDA is incapable of protecting US ‘against another Vioxx’. BMJ. 2004; 329: 1253.
19 Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211. 21 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts
medicine and politics. The New Republic. 2002 Dec 16: 27–41.
22 Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.
23 Moore TJ. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.
24 Cowley AJ, Skene A, Stainer K, et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993; 40: 161–6.
25 EMA. European Medicines Agency Widens Public Access to Documents. Press release.
2010 Nov 30.
26 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. Official Journal of the European Communities. 2001; L145: 43–8.
27 Hawkes N. Lobby groups call for closure of ‘revolving door’ between drug regulators and industry. BMJ. 2011; 343: d8335.
28 European Medicines Agency. Access to clinical-trial data and transparency.
Workshop report. 2012. Available online at: www.ema.europa.eu/docs/en_GB/document_library/Report/2012/12/WC500135841.p (accessed December 2012).
29 Editorial. [Straight talk]. Information. 2004 June 30.
30 Alfter B, Teugels M, Bouma J. Media lift lid on secret reports on drug side-effects.
Euobserver. 2008 Oct 22.
31 Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995. 32 Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. BMJ. 2011; 343:
d4203.
33 Jüni P, Reichenbach S, Egger M. COX 2 inhibitors, traditional NSAIDs, and the heart.
BMJ. 2005; 330: 1342–3.
34 Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.
35 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
36 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
37 Jørgensen AW. Robustness of results and conclusions in systematic reviews, trials and abstracts [PhD thesis]. Copenhagen: University of Copenhagen; 2011.
38 Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337: 581–8.
39 Mullard A. Mediator scandal rocks French medical community. Lancet. 2011; 377: 890–2.
40 Mintzes B. New UK guidance on industry-health professional collaboration. BMJ.
2012; 344: e3952.
41 Padwal R, Kezouh A, Levine M, et al. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond). 2007; 31: 1567–70.
42 Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012; 367: 1577–9.
43 Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008; 6: 34.
12
References
1 Tansey B. Huge penalty in drug fraud: Pfizer settles felony case in Neurontin off-label promotion. San Francisco Chronicle. 2004 May 14.
2 Harris G. Pfizer to pay $430 million over promoting drug to doctors. New York Times.
2004 May 14.
3 Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ. 2004; 328: 1217. 4 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about
it. New York: Random House; 2004.
5 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
6 Petersen M. Suit says company promoted drug in exam rooms. New York Times. 2002 May 15.
7 Landefeld CS, Steinman MA. The Neurontin legacy – marketing through misinformation and manipulation. N Engl J Med. 2009; 360: 103–6.
8 Petersen M. Court papers suggest scale of drug’s use. New York Times. 2003 May 30. 9 Dickersin K. Reporting and other biases in studies of Neurontin for migraine,
psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain. Available online at: www.pharmalot.com/wp-content/uploads/2008/10/neurontin-dickersin-2.pdf (accessed 10 December 2008).
10 Saul S. Experts conclude Pfizer manipulated studies. New York Times. 2008 Oct 8. 11 Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of
antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.
12 Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
13 Krumholz SD, Egilman DS, Ross JS. Study of Neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. Arch Intern Med. 2011; 171: 1100–7.
14 Adams C, Young A. Off-label prescription case reflects federal concern over unsafe uses. Knight Ridder Newspapers. 2004 May 14.
15 Voris B, Lawrence J. Pfizer Told to Pay $142.1 million for Neurontin Fraud. Bloomberg.
2010 March 25.
13
References
1 Tanne JH. Merck appeals rofecoxib verdict. BMJ. 2007; 334: 607.
2 Lenzer J. FDA is incapable of protecting US ‘against another Vioxx’. BMJ. 2004; 329: 1253.
3 Krumholz HM, Ross JS, Presler AH, et al. What have we learned from Vioxx? BMJ.
2007; 334: 120–3.
4 Topol EJ. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med.
2004; 351: 1707–9.
5 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
6 Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.
7 Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006; 296: 1653–6.
8 Topol E. Arthritis medicines and cardiovascular events – ‘house of coxibs’. JAMA. 2005;
293: 366–8.
9 Psaty BM, Furberg CD. COX-2 inhibitors – lessons in drug safety. N Engl J Med. 2005;
352: 1133–5.
10 US Senate Finance Committee. Testimony of David J Graham, MD, MPH. 2004 Nov
18. Available online at: www.finance.senate.gov/imo/media/doc/111804dgtest.pdf (accessed 21 February 2013).
11 US Food and Drug Administration. Memorandum. 2001. Available online at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf (accessed 23 June 2009).
12 Weaver AL, Messner RP, Storms WW, et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol. 2006; 12: 17–25.
13 Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520–8.
14 Armstrong D. The New England Journal missed Vioxx warning signs. 2006 May 15.
Available online at: www.post-gazette.com/pg/06135/690336-114.stm (accessed 27 November 2012).
15 Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006. 10.1056/NEJMe068054. Accessed 23 Feb 2006.
16 Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., ‘Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,’ N Engl J Med 2000;343:1520–8. N Engl J Med. 2005; 353: 2813–14.
17 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286: 954–9.
18 Liévre M, Abadie E, on behalf of the French Marketing Authorization Committee.
Discontinuation of Vioxx. Lancet. 2005; 365: 23–4.
19 Konstam MA, Weir MR, Reicin A. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001; 104: 2280–8.
20 Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002; 89: 204–9.
21 Corporate sponsorship. American Heart Association. Updated 2012 Oct 25. Available online at: www.heart.org/HEARTORG/Giving/ForCompanies/SponsorshipOpportunities/Corpor Sponsorship_UCM_321431_Article.jsp (accessed 31 October 2012).
22 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
23 Sanon S, Patel R, Eshelbrenner C, et al. Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist. Am J Cardiol. 2012; 110 supplement: 13B–23B.
24 Hill KP, Ross JS, Egilman DS, et al. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008; 149: 251–8.
25 Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003; 139: 539–46.
26 Berenson A. Evidence in Vioxx suits shows intervention by Merck officials. New York Times. 2005 Apr 24.
27 Ross JS, Hill KP, Egilman DS, et al. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
JAMA. 2008; 299: 1800–2.
28 Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Eur J Clin Pharmacol. 2010; 66: 341–7.
29 Grant B. Merck published fake journal. The Scientist. 2009. Available online at: www.the-scientist.com/blog/display/55671 (accessed 23 June 2009).
30 Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.
31 Psaty BM, Furberg CD. COX-2 inhibitors – lessons in drug safety. N Engl J Med. 2005;
352: 1133–5.
32 Waxman HA. The lessons of Vioxx – drug safety and sales. N Engl J Med. 2005; 352: 2576–8.
33 Waxman HA. The marketing of Vioxx to physicians. Memorandum. Congress of the United States. 2005 May 5.
34 Frazier KC. The lessons of Vioxx. N Engl J Med. 2005; 353: 1420.
35 Waxman HA. The lessons of Vioxx. N Engl J Med. 2005; 353: 1420–1.
36 Kim PS, Reicin AS. Rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 2875–6. 37 Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with
rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–102.
38 Nissen SE. Adverse cardiovascular effects of rofecoxib. N Engl J Med. 2006; 355: 203– 4.
39 Correction. N Engl J Med. 2006; 355: 221.
40 Topol E. Rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 2877–8. 41 Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for
Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008; 299: 1813–17.
42 Madigan D, Sigelman DW, Mayer JW, et al. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J. 2012; 164: 186–93.
43 Juhlin R. [MSD about Vioxx]. Läkartidningen. 2004; 46: 3720–1.
44 Whelton RS. Effects of excessive CEO pay on U.S. society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
45 Department of Justice. U.S. pharmaceutical company Merck Sharp & Dohme sentenced in connection with unlawful promotion of Vioxx. 2012 April 19.
46 Charatan F. 94% of patients suing Merck over rofecoxib agree to terms. BMJ. 2008;
336: 580–1.
47 Berenson A. Merck agrees to settle Vioxx suits for $4.85 billion. New York Times.
2007 Nov 9.
14
References
1 Celecoxib and the CLASS trial: data massaging by industry. Prescrire International.
2002; 11: 190–1.
2 Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247–55.
3 Okie S. Missing data on Celebrex. Washington Post. 2001 Aug 5.
4 Lichtenstein DR, Wolfe MM. COX-2-Selective NSAIDs: new and improved? JAMA.2000; 284: 1297–9.
5 Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002; 324: 1287–8.
6 Thomas K. In documents on pain drug Celebrex, signs of doubt and deception. New York Times. 2012 June 24.
7 Lu HL. Statistical Reviewer Briefing Document for the Advisory Committee. FDA. 2000; NDA20-998.
8 FDA. Summary minutes, AAC & DSaRM. 2005 Feb 16–18. Available online at: www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1: Final.htm (accessed February 2005).
9 Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002; 325: 619.
10 Deeks JJ, Smith LA, Bradley MD. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. BMJ. 2003; 326: 335–6.
11 Geis GS. Pharmacia’s response to editorial. BMJ. 2002; 325: 161–2.
12 Jüni P, Rutjes AWS, Dieppe P. Authors’ reply. BMJ. 2002; 325: 163–4.
13 Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001; 286: 2398.
14 White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89: 425–30.
15 Andrade M. In clear sight. BMJ. 2009; 339: 538–40.
16 Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071–80.
17 Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.
18 Crone M. [Pfizer gets additional fine for illegal marketing]. Berlingske. 2004 Nov 16. 19 Gøtzsche PC. [COX-2 inhibitors and other nonsteroidal, anti-inflammatory drugs –what future?] Ugeskr Læger. 2006; 168: 1972–3.
20 DeAngelis CD, Thornton JP. Preserving confidentiality in the peer review process.
JAMA. 2008; 299: 1956.
21 Dyer C. Pfizer asks journal for comments made by peer reviewers. BMJ. 2008; 336: 575.
22 Feeley J, Van Voris B. Pfizer destroyed arthritis drugs’ files, investors claim.
Bloomberg. 2012 Nov 21. Available online at: www.bloomberg.com/news/2012-11- 21/pfizer-destroyed-arthritis-drugs-files-investors-claim.html (accessed 10 July2013).
23 Mamdani M, Juurlink DN, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ. 2004; 328: 1415–6.
24 FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345: 433–42.
25 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
26 Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. 1997; 11: 283–91.
27 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
28 Gibson L. Drug company sues Spanish bulletin over fraud claim. BMJ. 2004; 328: 188.
29 Laporte J-R. Merck Sharpe and Dohme versus Laporte. Lancet. 2004; 364: 416.
30 Honig P. Merck Sharp and Dohme versus Laporte. Lancet. 2004; 363: 1079–80.
15
References
1 Gale EAM. Post-marketing studies of new insulins: sales or science? BMJ. 2012; 344: e3974.
2 Harris G, Pear R. Drug maker’s efforts to compete in lucrative insulin market are under scrutiny. New York Times. 2006 Jan 28.
3 Yudkin JS. Post-marketing observational trials and catastrophic health expenditure.
BMJ. 2012; 344: e3987.
4 Hawkes N. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court. BMJ. 2012; 345: e8396.
5 Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001; 15: 1729–36.
6 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
7 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag 2007.
8 Tuffs A. Germany sees rise in post-marketing studies. BMJ. 2009; 339: b4199.
9 Hyde R. German doctors free to take cash from drug firms. Lancet. 2012; 380: 551.
10 Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008; 336:2–3.
11 McKay AB. Overprescribing PPIs. BMJ. 2008; 336: 109.
12 Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012; 344: e1086.
13 Lenzer J. FDA is criticised for licensing high dose donepezil. BMJ. 2011; 342: d3270. 14 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
16
References
1 Strengthening the credibility of clinical research. Lancet. 2010; 375: 1225.
2 Nissen S. Slides presented at the FDA advisory meeting about rosiglitazone. 2010 July 13.
3 Cohen D. Rosiglitazone: what went wrong? BMJ. 2010; 341: 530–4.
4 Harris G. Diabetes drug maker hid test data. New York Times. 2010 July 13.
5 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
6 Khan H, Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case.
ABC News. 2010 April 27.
7 Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
8 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457–71.
9 Nissen SE. Setting the RECORD straight. JAMA. 2010; 303: 1194–5.
10 Mitka M. Critics press FDA to act on evidence of rosiglitazone’s cardiac safety issues.
JAMA. 2010; 303: 2341–2.
11 Moynihan R. Rosiglitazone, marketing, and medical science. BMJ. 2010; 340: c1848. 12 Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for
cardiovascular outcomes – an interim analysis. N Engl J Med. 2007; 357: 28–38.
13 Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009, 373: 2125–35.
14 Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010; 304: 793–4.
15 Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardialinfarction. N Engl J Med. 2007; 357: 67–9.
16 Graham D, Gelperin K. More on advisory committee decision. BMJ. 2010; 341: 519. 17 Mello MM, Goodman SN, Faden RR. Ethical considerations in studying drug safety –
the Institute of Medicine report. N Engl J Med. 2012; 367: 959–64.
18 Cohen D. FDA puts rosiglitazone post-marketing trial on hold. BMJ. 2010; 341: c4017.
19 Tanne JH. GSK is accused of trying to suppress editorial on rosiglitazone. BMJ. 2010;340: c2654.
20 Slaoui M. The rise and fall of rosiglitazone: reply. Eur Heart J. 2010; 31: 1282–4.
21 FDA Drug Safety Communication. Avandia (Rosiglitazone) Labels now Contain Updated Information about Cardiovascular Risks and Use in Certain Patients. 2011 Mar 3.
22 Wang AT, McCoy CP, Murad MH, et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010; 340: c1344.
23 Lehman R, Yudkin JS, Krumholz HM. Licensing drugs for diabetes. BMJ. 2010; 341: 513–14.
24 Solomon DH, Winkelmayer WC. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA. 2007; 298: 1216–18.
25 Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279–89.
26 Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004; 27: 1647–53.
27 PROactive Study Executive Committee and Data and Safety Monitoring Committee.
PROactive study. Lancet. 2006; 367: 982.
28 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006; 295: 1645–6.
29 Chan A-W, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004; 291: 2457–65.
30 Chan A-W, Hróbjartsson A, Jørgensen KJ, et al. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008; 337: a2299.
31 Jack A. European drugs watchdog to step up scrutiny. Financial Times. 2012 March 6. 32 Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet.2011; 378: 1543–4.
33 European Medicines Agency. Assessment report, Pioglitazone ratio. EMA/391408/2012.
2012 May 24.
34 Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.
35 Hillaire-Buys D, Faillie JL. Pioglitazone and the risk of bladder cancer. BMJ. 2012;
344: e3500.
36 FDA Drug Safety Communication. Update to Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer. 2011 June 6.
37 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
38 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
39 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
40 Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005; 294: 2581–6.
41 Brophy JM. Selling safety – lessons from muraglitazar. JAMA. 2005; 294: 2633–5. 42 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
43 Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; 3: CD002966.
44 Wikipedia. Metformin. Available online at: http://en.wikipedia.org/wiki/Metformin (accessed 12 October 2012).
45 Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology. 2011; 141: 20–3.
46 Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141: 150–
6.
47 Gøtzsche PC, Mæhlen J, Zahl PH. What is publication? Lancet. 2006; 368: 1854–6. 48 Public citizen to FDA: pull diabetes drug Victoza from market immediately. Public
Citizen. 2012 April 19.
49 Lindeberg M. [Novo Nordisk has sent warnings about the cancer risk with its diabetes drug Victoza to US physicians]. Berlingske. 2011 June 14.
50 US Food and Drug Administration. FDA Approves New Treatment for Type 2 Diabetes.
2010 Jan 25.
51 Maxmen A. Debate on diabetes drugs gathers pace: petition unveils unnerving reports on potential carcinogenicity of GLP-1 mimics. Nature. 2012 April 30.
17
References
1 Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
2 Caplan PJ. They Say You’re Crazy: how the world’s most powerful psychiatrists decide who’s normal. Jackson: Da Capo Press; 1995.
3 Angell M. ‘The illusions of psychiatry’: an exchange. New York Rev Books. 2011 Aug 18.
4 Moynihan R. Medicalization. A new deal on disease definition. BMJ. 2011; 342: d2548.
5 Harris G, Carey B, Roberts J. Psychiatrists, children and drug industry’s role. New York Times. 2007 May 10.
6 Insel TR. Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA. 2010; 303: 1192–3.
7 Moynihan R. Is the relationship between pharma and medical education on the rocks? BMJ. 2008; 337: 484–5.
8 Watts G. More psychiatrists attack plans for DSM-5. BMJ. 2012; 344: e3357. 9 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical
companies are turning us all into patients. New York: Nation Books; 2005.
10 Boseley S. Prozac, used by 40m people, does not work say scientists. The Guardian. 2008 Feb 26.
11 Brown J, O’Brien PMS, Marjoribanks J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD001396.
12 [Work environment and treatment modalities in Danish psychiatry]. Nordjyske Medier; 2007.
13 Total sales of medicinal products. Danish Medicines Agency. 2011.
14 IMS Health. IMS Health Reports U.S. Prescription Sales Grew 5.1 percent in 2009, to
$300.3 billion. Press release. 2010 April 1.
15 Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005; 352: 2515–23.
16 Spence D. The psychiatric oligarchs who medicalise normality. BMJ. 2012; 344: e3135.
17 Gross J. Checklist for camp: bug spray, sunscreen, pills. New York Times. 2006 July 16.
18 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
19 Schwarz A. Attention disorder or not, pills to help in school. New York Times.
2012 Oct 9.
20 GfK Denmark. [Focus group about treatment of ADHD in children and adolescents]. Letter. 2011 Nov 23.
21 Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010. 22 Morbidity and Mortality Weekly Report. Current depression among adults –
United States, 2006 and 2008. JAMA. 2010; 304: 2233–5.
23 The Patient Health Questionnaire (PHQ-9). Available online at: www.agencymeddirectors.wa.gov/Files/depressoverview.pdf (accessed 20
October 2012).
24 Healy D. Let Them Eat Prozac. New York: New York University Press; 2004. 25 Frances A. Antidepressant use has gone crazy: bad news from the CDC.
Psychiatric Times. 2011 Oct 28.
26 Friedman RA. Grief, depression, and the DSM-5. N Engl J Med. 2012; 366: 1855– 7.
27 Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products.
Int J Risk Saf Med. 2011; 23: 125–32.
28 Open letter to the DSM-5. Online petition. Available online at: www.ipetitions.com/petition/dsm5/.
29 Spence D. Bad medicine: bipolar II disorder. BMJ. 2011; 342: d2767.
30 Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004; 158: 773–80.
31 Shea SE, Gordon K, Hawkins A, et al. Pathology in the Hundred Acre Wood: a neurodevelopmental perspective on A.A. Milne. CMAJ. 2000; 163: 1557–9.
32 The creation of the Prozac myth. The Guardian. 2008 Feb 27.
33 Spence D. Bad medicine: adult attention-deficit/hyperactivity disorder. BMJ.
2011; 343: d7244.
34 Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011; 7: 729–44.
35 More fraud from drug giant GlaxoSmithKline companies – court documents show. Blog post. Child Health Safety. 2010 Dec 1. Available online at: http://childhealthsafety.wordpress.com/2010/12/01/more-fraud-from-drug-giant- glaxosmithkline-companies/ (accessed 17 July 2013).
36 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy.
2007 July: 991–1012.
37 Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms.
Neuropsychopharmacol. 2006; 31: 1345–55.
38 Volpe M. Dr Charles Nemeroff and Emory University’s culture of corruption.
Blog post. The Provocateur. 2009 July 10. Available at: http://theeprovocateur.blogspot.co.nz/2009/07/dr-charles-nemeroff-and-emorys- culture.html (accessed 17 July 2013).
39 Nugent T. Profile in courage: A beleaguered whistle-blower physician fights for patients and jobs – and wins. Opednews. 2012 Nov 1.
40 Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342: 1462–70.
41 Angell M. Is academic medicine for sale? N Engl J Med. 2000; 342: 1516–8.
42 Larson JC, Ensrud KE, Reed SD, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305: 267–74.
43 Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011; 343: d4551.
44 McHugh PR, Slavney PR. Mental illness – comprehensive evaluation or checklist? N Engl J Med. 2012; 366: 1853–5.
45 Kleinman A. Rebalancing academic psychiatry: why it needs to happen – and soon. Br J Psych. 2012; 201: 421–2.
46 Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.
47 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
48 Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005; 6: 241–6.
49 Andrews PW, Kornstein SG, Halberstadt LJ, et al. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol. 2011; 2: 159.
50 Medawar C, Herxheimer A, Bell A, et al. Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post- marketing drug surveillance. Int J Risk Saf Med. 2002; 15: 161–9.
51 Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012; 107: 900–8.
52 Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med. 2003/2004; 16: 5–19.
53 El-Mallakh RS, Gao Y, Jeannie Roberts R. Tardive dysphoria: the role of longterm antidepressant use in inducing chronic depression. Med Hypotheses. 2011;76: 769–73.
54 Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS One. 2010; 5: e15337.
55 Healy D. Reply to D.Wilkinson – Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. J Psychopharmacol. 1999; 13: 421.
56 Orriols L, Delorme B, Gadegbeku B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010; 7: e1000366.
57 FDA Approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets. 2007 June 15. Available online at: www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf (accessed 17
July 2013).
58 Thombs BD, Arthurs E, El-Baalbaki G, et al. Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review. BMJ. 2011; 343: d4825.
59 Gilbody S, House A, Sheldon T. Screening and case finding instruments for depression. Cochrane Database Syst Rev. 2005; 4: CD002792.
60 Lundh A. [Is there evidence for screening for depression]? Ugeskr Læger. 2008;
170: 1479.
61 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
62 Medawar C, Hardon A. Medicines out of Control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.
63 van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev. 2012; 7: CD007139.
64 Montejo A, Llorca G, Izquierdo J, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry. 2001; 62(Suppl. 3): 10–21.
65 Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003; 5: 153–7.
66 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer.
New York: Bloomsbury; 2007.
67 Boseley S. They said it was safe. The Guardian. 1999 Oct 30.
68 Healy D. Pharmageddon. Berkeley: University of California Press; 2012. 69 Internal Eli Lilly memo. Bad Homburg. 1984 May 25.
70 Zirapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.
71 Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet.
Available online at: www.conspiracyplanet.com/channel.cfm? channelid=55&contentid=4181&page=2 (accessed 28 June 2012).
72 Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147: 207–10.
73 Lenzer J. FDA to review ‘missing’ drug company documents. BMJ. 2005; 330: 7. 74 Bouchy C. Internal Eli Lilly memo. 1990 Nov 13.
75 Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998; 44: 77–87.
76 Barbui C, Cipriani A, Brambilla P, et al. ‘Wish bias’ in antidepressant drug trials?
J Clin Psychopharmacol. 2004; 24: 126–30.
77 European Medicines Agency (1999/2000). EMEA/CPMP/2775/99.
78 Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.
79 Lenzer J. Secret US report surfaces on antidepressants in children. BMJ. 2004;
329: 307.
80 Jurand SH. Lawsuits over antidepressants claim the drug is worse than the disease. American Association for Justice. 2003 Mar 1. Available online at: www.thefreelibrary.com/_/print/PrintArticle.aspx?id=99601757 (accessed 23
December 2012).
81 Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008; 178: 296–305.
82 Serna MC, Cruz I, Real J, et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry. 2010; 25: 206–13.
83 Ioannidis JPA. Ranking antidepressants. Lancet. 2009; 373: 1759–60.
84 Laughren TP. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). 2006 Nov 16. Available online at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf (accessed 22 October 2012).
85 Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis, JAMA. 2010; 303: 47–53.
86 DeRubeis, Fournier JC. Depression severity and effect of antidepressant medications. JAMA. 2010; 303: 1599.
87 Johnson LA. Pfizer disputes claim against antidepressant. USA Today. 2013 Jan31.
88 Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000 Sep–Oct; 62: 633–8.
89 Rimer J, Dwan K, Lawlor DA, et al. Exercise for depression. Cochrane Database Syst Rev. 2012; 7: CD004366.
90 Haug TT, Blomhoff S, Hellstrøm K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003; 182: 312–18.
91 Wikipedia. GlaxoSmithKline. Available online at: http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).
92 Herxheimer A. Turbulence in UK medicines regulation: A stink about SSRI antidepressants that isn’t going away. In: Glavanis K, O’Donovan O, editors. Power, Politics and Pharmaceuticals: drug regulation in Ireland in the global context. Cork: Cork University Press; 2008.
93 Grassley CE. Paxil. Speech at the US Senate. 2008 June 11.
94 Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol. 1990/1991; 1: 193–8.
95 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
96 Hansen EH, Gyldmark M. [Psychotropic drug use. Distribution and development]. Copenhagen: Sundhedsstyrelsen; 1990.
97 Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005; 331: 1169–73.
98 de Gage SB, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231.
99 Nielsen M. Selective Serotonin Reuptake Inhibitors (SSRI) – sales, withdrawal reactions and how drug regulators reacted to this with benzodiazepines as comparator [PhD thesis]. Copenhagen: University of Copenhagen; 2013.
100 Fava GA, Bernardi M, Tomba E, et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007; 10: 835–8.
101 Medawar C. The antidepressant web – marketing depression and making medicines work. Int J Risk Saf Med. 1997; 10: 75–126.
102 Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993 Fall; 8(3): 189–95.
103 Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003; 361:653–61.
104 House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
18
References
1 Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40: 762–72.
2 Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
3 Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Safety Med. 2008; 20: 73–81.
4 Jureidini JN, McHenry LB. Conflicted medical journals and the failure of trust.
Accountability in Research. 2001; 18: 45–54.
5 More fraud from drug giant GlaxoSmithKline companies – court documents show. Child Health Safety. 2010 Dec 1.
6 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
7 Boyce J. Disclosure of clinical trial data: why exemption 4 of the freedom of information act should be restored. Duke Law & Technology Review. 2005; 3.
8 Jurand SH. Lawsuits over Antidepressants Claim the Drug is worse than the Disease.
American Association for Justice. 2003 Mar 1. Available online at: www.thefreelibrary.com/_/print/PrintArticle.aspx?id=99601757 (accessed 23 Dec 2012).
9 Healy D. Pharmageddon. Berkeley: University of California Press; 2012.
10 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
11 Kingston A. A national embarrassment. Maclean’s Magazine. 2012 Oct 17. 12 The creation of the Prozac myth. The Guardian. 2008 Feb 27.
13 Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.
14 Furukawa TA. All clinical trials must be reported in detail and made publicly available. Lancet. 2004; 329: 626.
15 Harris G. Merck says it will post the results of all drug trials. New York Times. 2004 Sept 6.
16 Lenzer J. Secret US report surfaces on antidepressants in children. BMJ. 2004; 329: 307.
17 Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329: 1308.
18 Giles J. Did GSK trial data mask Paxil suicide risk? New Scientist. 2008 Feb 8. 19 Healy D. SSRIs and deliberate self-harm. Br J Psychiatry. 2002; 180: 547.
20 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000; 57: 311–17.
21 Power N, Lloyd K. Response from Pfizer. Br J Psychiatry. 2002; 180: 547–8.
22 Rockhold F, Metz A, Traber P. Response from GlaxoSmithKline. Br J Psychiatry. 2002;
180: 548.
23 Healy D. Did regulators fail over selective serotonin reuptake inhibitors? BMJ. 2006;
333: 92–5.
24 Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003; 183: 22–7.
25 Lenzer J. FDA to review ‘missing’ drug company documents. BMJ. 2005; 330: 7. 26 Boseley S. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian. 2002 Feb 7.
27 Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004; 363: 1341–5.
28 Seroxat/Paxil Adolescent Depression. Position piece on the phase III clinical studies.
GlaxoSmithKline document. 1998 Oct.
29 Laughren TP. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). 2006 Nov 16. Available online at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf (accessed 22 October 2012).
30 Internal Eli Lilly memo. Bad Homburg. 1984 May 25.
31 Eli Lilly memo. Suicide Report for BGA. Bad Homburg. 1990 Aug 3.
32 Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 1995; 5: 5–13.
33 GlaxoSmithKline. Briefing Document. Paroxetine adult suicidality analysis: major depressive disorder and non-major depressive disorder. 2006 April 5.
34 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ. 2005; 330: 385.
35 Healy DT. Risk of suicide. BMJ. 2005 Feb 18. Available online at: www.bmj.com/content/330/7488/385?tab=responses (accessed 18 December 2012).
36 Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005; 330: 396.
37 Menzies KB. 2006 PDAC Regarding the Results of FDA’s Ongoing Meta-Analysis of Suicidality Data from Adult Antidepressant Trials. FDA. 2006 Dec 1.
38 Schelin EM. [Healthy skepticism is the best medicine]. Ugeskr Læger. 2010; 172: 3361. 39 Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ.
2006; 332: 1444–7.
40 Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002; 7(4 Suppl. 1): 40–4.
41 Escitalopram (Lexapro) for depression. Medical Letter. 2002; 44: 83–4.
42 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
43 Carlsen LT. [A difficult balance]. Tænk + Test. 2003; 32: 30–3.
44 Lindberg M. [Interesting regard for exports]. Dagens Medicin. 2002 Nov 29. 45 [The Danish Drug Agency gives Lundbeck hindwind]. Politiken. 2004 Sept 13.
46 [Treatment with antidepressants]. Danish Institute for Rational Drug Therapy. 2004 Sept 10.
47 Dyer O. Lundbeck broke advertising rules. BMJ. 2003; 326: 1004.
48 Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; 2: CD006532.
49 Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252–60.
50 Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011; 155: 772–85.
51 Dyer O. Lundbeck broke advertising rules. BMJ. 2003; 326: 1004.
52 Masculine. Available online at: www.sprunk-jansen.com/da (accessed 2012 October 28).
53 Svansø VL. [Lundbeck needs to fight for the company’s image]. Berlingske. 2011 May 14.
54 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
55 US Department of Justice. Drug Maker Forest Pleads Guilty; to pay more than
$313 million to resolve criminal charges and False Claims Act allegations. 2010 Sept 15. 56 Hyltoft V. [Lundbeck partner in settlement about suicides]. Berlingske. 2011 Feb 8. 57 Meier B, Carey B. Drug maker is accused of fraud. New York Times. 2009 Feb 25.
58 Edwards J. Suit vs. Forest Labs names execs linked to alleged lies about Lexapro, Celexa. CBS News, Moneywatch. 2009 Feb 26.
59 Meier B. A medical journal quandary: how to report on drug trials. New York Times.
2004 June 21.
60 Harris G. Document details plan to promote costly drug. New York Times. 2009 Sept 1.
61 US Senate, Committee on Finance. Letter about Lexapro documents. 2009 Aug 12.
Available online at: www.nytimes.com/packages/pdf/politics/20090831MEDICARE/20090831_MEDICARE (accessed 2011).
62 Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012; Aug 6: 1–10.
63 Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet.
2009; 373: 4–5.
64 Rosenheck RA. Pharmacotherapy of first-episode schizophrenia. Lancet. 2008; 371: 1048–9.
65 Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371: 1085–97.
66 Stark J. McGorry aborts teen drug trial. Sydney Morning Herald. 2011 Aug 21. 67 Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation
antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31–41.
68 Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002; 190: 583–92.Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 1998; 317: 1181–4.
69 Pfizer memorandum. 1989 April 26.
70 Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; 2: CD001359.
71 Lenzer J. Drug company tries to suppress internal memos. BMJ. 2007; 334: 59.
72 Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321: 1371–6.
73 Larsen N-E. [New medicine has considerable adverse effects]. Dagens Medicin. 2001 Sept 27.
74 Sheller SA. The Largest Pharma Fraud Whistleblower Case in US history totaling
$1.4 billion. Press release. 2009 Jan 15. Available online at: www.reuters.com/article/2009/01/15/idUS182128+15-Jan-2009+PRN20090115 (accessed 17 July 2013).
75 Berenson A. Eli Lilly said to play down risk of top pill. New York Times. 2006 Dec 17. 77 Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine:
evidence from internal industry documents. Bioethical Inquiry. 2010. DOI 10.1007/s11673-010-9208-8.
78 Dyer O. Lilly investigated in US over the marketing of olanzapine. BMJ. 2007; 334: 171.
79 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294: 1934–43.
80 McGauran N, Wieseler B, Kreis J, et al. Reporting bias in medical research – a narrative review. Trials. 2010; 11: 37.
18
References
1 Adams S. Roche versus Adams. London: J. Cape; 1984.
2 Kesselheim AS, Studdert DM, Mello MM. Whistle-blowers’ experiences in fraud litigation against pharmaceutical companies. N Engl J Med. 2010; 362: 1832–9.
3 Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press;
2006.
4 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
5 Drug Industry Document Archive. University of California, San Francisco. Available online at: http://dida.library.ucsf.edu/search?query=argumentative (accessed 21 September 2012).
6 Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.
7 Shuchman M. Drug company threatens legal action over Canadian guidelines. BMJ.
1999; 319: 1388.
8 Tougaard H, Hundevadt K. [The golden promises of the gynaecologists].
Jyllandsposten. 2004 Jan 18.
9 Villesen K. [The drug companies earn fortunes while raising doubt]. Information. 2011 Dec 9.
10 Glaxo ‘downplayed’ warning on heart-attack risk from AIDS drug. The Independent.
2008 May 12.
11 Brix SM. [Researcher receives death threats]. Universitetsavisen. 2008; 14: 5. 12 Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl Starch 130/0.42 versus
Ringer’s acetate in severe sepsis. N Engl J Med. 2012; 367: 124–34.
13 Klawitter U, Stief M. Demand for correction of article entitled ‘Hydroxyethyl Starch 130/0.4 versus Ringer’s Acetate in Severe Sepsis’ (published online on June 27, 2012). Letter. 2012 July 9.
14 Corrections. N Engl J Med. 2012; 367: 481.
15 Kupferschmidt K. Squabble Over NEJM paper puts spotlight on antishock drug.
ScienceInsider. 2012 Aug 2.
16 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
17 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
18 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
19 Fries JF. Letter to Raymond Gilmartin re: physician intimidation. 9 Jan, 2001. Merck. Bates No MRK-ABH0002204 to MRK-ABH0002207. Available online at: www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Fries2001.pdf (accessed 10October 2007).
20 Wood S. Eric Topol loses provost/chief academic officer titles at Cleveland Clinic and Lerner College. Heartwire. 2005 Dec 12.
21 Rout M. Vioxx maker Merck and Co drew up doctor hit list. The Australian. 2009 April 1.
22 Blowing the whistle on the FDA: an interview with David Graham. Multinational
Monitor. 2004; 25(12).
23 Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329: 1308.
24 Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365: 475–81.
25 Lenzer J. Public interest group accuses FDA of trying to discredit whistleblower. BMJ.
2004; 329: 1255.
26 Lenzer J. US government agency to investigate FDA over rofecoxib. BMJ. 2004; 329: 935.
27 Lenzer J. FDA bars own expert from evaluating risks of painkillers. BMJ. 2004; 329: 1203.
28 Lenzer J. Pfizer criticised over delay in admitting drug’s problems. BMJ. 2004; 329: 935.
29 Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004;
364: 1995–6.
30 Eaton L. Editor claims drug companies have a ‘parasitic’ relationship with journals.
BMJ. 2005; 330; 9.
31 Andersen NV, Drachmann H. [Pharmaceutical giant blacklisted]. Politiken. 2004 Mar 25.
32 [Verdict in the Press Council in case 2004-6-45]. Pressenævnet. 2004 Aug 18.
33 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
34 Mello MM, Clarridge BR, Studdert DM. Academic medical centers’ standards for clinical-trial agreements with industry. N Engl J Med. 2005; 352: 2202–10.
35 Williams HC. Evening primrose oil for atopic dermatitis. BMJ. 2003; 327: 1358–9. 36 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
37 Boseley S. Bitter pill. The Guardian. 2001 May 7.
38 Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8– 24.
39 Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.
40 Healy D. Medical partisans? Why doctors need conflicting interests. Aust N Z J Psychiatry. 2012; 46: 704–7.
41 Baylis F. The Olivieri debacle: where were the heroes of bioethics? J Med Ethics.
2004; 30: 44–9.
42 Dyer C. Aubrey Blumsohn, academic who took on industry. BMJ. 2010; 340: 22–3. 43 Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4.
44 Revill J. How the drugs giant and a lone academic went to war. Observer. 2005 Dec 4.
45 Dyer C. Professor to face GMC over his claim to have seen full trial data. BMJ. 2009;
339: 774–5.
46 Gornall J. A very public break-up. BMJ. 2010; 340: 180–3.
47 Wilmshurst P. The effects of the libel laws on science – a personal experience. Radical Statistics. 2011: 104: 13–23.
48 Wikipedia. Simon Singh. Available online at: http://en.wikipedia.org/wiki/Simon_Singh (accessed 17 June 2010).
49 Singh S. This is goodbye. The Guardian. 2010 March 12.
50 Dyer C. Charity sets up fund to defend researcher being sued for libel. BMJ. 2008;
337: 1313.
51 Tanne JH. FDA places ‘black box’ warning on antidiabetes drugs. BMJ. 2007; 334: 1237.
52 Burton B. Diabetes expert accuses drug company of ‘intimidation’. BMJ. 2007; 335: 1113.
53 Cohen D. Drug study secrecy puts lives at risk. Index on Censorship. 2011 Nov 29. 54 DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research.
JAMA. 2010; 303: 1196–8.
55 Lenzer J, Brownlee S. Reckless medicine. Discover. 2010; 11: 64–76.
56 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006; 295: 1645–6.
57 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. [Constraints on publication rights in industry-initiated clinical trials: secondary publication]. Ugeskr Læger. 2006; 168: 2467–9.
58 Gornall J. Research transparency: industry attack on academics. BMJ. 2009; 338: 626–8.
20
References
1 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
2 Federal Trade Commission. Generic Drug Entry Prior to Patent Expiration: an FTC study.
2002, July. Available online at: www.ftc.gov/os/2002/07/genericdrugstudy.pdf (accessed 1 November 2007).
3 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
4 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
5 Adams S. Roche versus Adams. London: J. Cape; 1984.
6 Clinard MB, Yeager PC. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
7 Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
8 Nelson R. Debate over ritonavir price increase gains momentum. Lancet. 2004; 363: 1369.
9 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
10 Hemmingsen MA. [Antidepressant medicine increases by 1200 percent in three months]. Dagens Medicin. 2010 Sept 17.
11 Andersen L. [Drug prices will be trenched]. Jyllandsposten. 2007 March 30.
12 Dilling S. [Price for cholesterol lowering drug explodes]. Politiken. 2007 March 28. 13 Svansø VL. [Lundbeck purchase costs a court case]. Berlingske. 2009 Feb 21.
14 Drug company granted monopoly – price of drug increases 15000%. Pioneer Press.
2011 March 14.
15 Messori A, Cicchetti A, Patregani L. Relating price determination to disease prevalence. BMJ. 2010; 341: 417–18.
16 Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.
17 PBS. The Other Drug War. Interview with Marcia Angell. 2002 Nov 26. Available online at: www.pbs.org/wgbh/pages/frontline/shows/other/interviews/angell.html (accessed 4 April 2005).
18 Steenberger A, Larsen K, Bundgaard B. [The minister of health wishes to discuss prioritisation with the regions]. Ugeskr Læger. 2011; 173: 472.
19 Svansø VL, Hyltoft V. [The regions at war with the drug industry]. Berlingske. 2011 Feb 3.
20 Quotations. Ugeskr Læger. 2010; 172: 1568.
21 Svansø VL, Hyltoft V. [Drug industry under pressure]. Berlingske. 2011 Feb 3. 22 Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on
drugs. BMJ. 2010; 340: 1224–7.
23 Mintzberg H. Patent nonsense: evidence tells of an industry out of social control.
CMAJ. 2006; 175: 374.
24 Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med. 2011; 364: 535–41.
25 Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
26 The Association of the British Pharmaceutical Industry. Guidance on Collaboration between Healthcare Professionals and the Pharmaceutical Industry. 2012 March 29.
Available online at: www.abpi.org.uk/our- work/library/guidelines/Pages/collaboration-guidance.aspx (accessed 27 December 2012).
27 Braillon A, Bewley S, Herxheimer A, et al. Marketing versus evidence-based medicine.
Lancet. 2012; 380: 340.
28 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
29 Beran D, Capewell S, de Courten M, et al. The International Diabetes Federation: losing its credibility by partnering with Nestlé? Lancet. 2012; 380: 805.
30 Danish Association of the Pharmaceutical Industry. [Revised collaborative agreement between the Medical Association and the Danish Association of the Pharmaceutical Industry about clinical trials and non-intervention studies]. 2010 June 1.
31 Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
32 Huskisson EC, Woolf DL, Balme HW, et al. Four new anti-inflammatory drugs: responses and variations. Br Med J. 1976; 1: 1048–9.
21
References
1 Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
2 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
3 Weingart SN, Wilson RM, Gibberd RW, et al. Epidemiology of medical error. BMJ.
2000; 320: 774–7.
4 Starfield B. Is US health really the best in the world? JAMA. 2000; 284: 483–5. 5 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in
hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200– 5.
6 Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001; 161: 2317–23.
7 Archibald K, Coleman R, Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011; 377: 1915.
8 Centers for Disease Control and Prevention. Leading Causes of Death. Available online at: www.cdc.gov/nchs/fastats/lcod.htm (accessed 5 February 2013).
9 Lenzer J. Anticoagulants cause the most serious adverse events, finds US analysis.
BMJ. 2012; 344: e3989.
10 Centers for Disease Control and Prevention. Tobacco-Related Mortality. Available online at: www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_morta (accessed 2 February 2013).
11 Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008; 25: 1021–31.
12 Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
13 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy.
2007 July: 991–1012.
14 Kassirer JP. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
15 Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006. 16 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New
York: Bloomsbury; 2007.
17 World Health Organization. World Health Report 2003 – shaping the future. 2003.
Available online at: www.who.int/whr/2003/annex_4_en.xls (accessed 20 December 2012).
18 Reinhardt UE, Hussey PS, Anderson GF. U.S. health care spending in an international context. Health Aff (Millwood). 2004; 23: 10–25.
19 Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889.
20 Starfield B, Shi L, Grover A, et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97.
21 World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e.6 (accessed 6
February 2013).
22 Wealth but not health in the USA. Lancet. 2013; 381: 177.
23 Nolte E, McKee CM. Measuring the health of nations: updating an earlier analysis.
Health Aff (Millwood). 2008; 27: 58–71.
24 Avendano M, Glymour MM, Banks J, et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8.
25 Jachuck SJ, Brierley H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5.
26 Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10:CD009009.
27 Johnston ME, Gibson ES, Terry CW, et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23.
28 Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44.
29 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
30 Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873.
31 Cacciotti J, Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the- Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013).
32 Berwick DM, Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16.
33 Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ.
2003; 326: 1156–7.
34 Tanne JH. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330. 35 Whelton RS. Effects of Excessive CEO Pay on U.S. Society. Available online at:
www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
36 Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8– 24.
37 Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007.
38 Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003.
39 Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
40 Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
41 Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995. 42 Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334:
1025.
43 Bloemen S, Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April.
44 Bassand J-P, Martin J, Rydén L, et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9.
45 Gøtzsche PC, Hansen M, Stoltenberg M, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9.
46 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
47 Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials. 1996; 17: 285–90.
48 Borst-Eilers E. Assessing hospital technology in the Netherlands: new treatments are paid for only if they are part of an evaluation. BMJ. 1993; 306: 226.
49 Garattini S, Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803– 5.
50 Liberati A, Traversa G, Moja LP, et al. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest. 2010; 40: 69–86.
51 Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
52 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
53 Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285: 437–43.
54 Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996; 313: 1390–3.
55 Goldbeck-Wood S. Denmark takes a lead on research ethics. BMJ. 1998; 316: 1189. 56 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
57 Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials.
Lancet. 2011; 378: 1995–6.
58 Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsors’ participation in conduct and reporting of industry trials: a descriptive study. Trials. 2012; 13: 146.
59 Heran BS, Wong MMY, Heran IK, et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003823.
60 Directive 2010/84/EU of the European Parliament and of the Council. 2010 Dec 15. 61 Gøtzsche PC, Liberati A, Luca P, et al. Beware of surrogate outcome measures. Int J
Technol Ass Health Care. 1996; 12: 238–46.
62 Apolone G, Joppi R, Bertele V, et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer. 2005; 93: 504–9.
63 Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002;325: 269–71.
64 Machin D, Stenning SP, Parmar MKB, et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol. 1997; 9: 100–14.
65 Soares HP, Kumar A, Daniels S, et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005; 293: 970–8.
66 Kumar A, Soares H, Wells R, et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children’s Oncology Group. BMJ. 2005; 331: 1295–8.
67 Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
68 Rochon PA, Fortin PR, Dear KB, et al. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993; 153: 243–8.
69 Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007; 297: 1233–40.
70 Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population – the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012; 367: 1972–4.
71 World Medical Association. Ethical Principles for Medical Research Involving Human Subjects. 2008. Available online at: www.wma.net/en/30publications/10policies/b3/ (accessed 17 July 2013).
72 Whitaker R. Anatomy of an Epidemic. New York: Random House; 2010.
73 Strom BL. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.
74 Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.
75 Newman M. Bitter pills for drug companies. BMJ. 2010; 341: c5095.
76 Alsman SW. [Hidden research led to wrong recommendations about happy pills].
Økonomisk Ugebrev. 2004 May 3.
77 Senate Republican Policy Committee. Legislative Notice No. 13. S. 1082 – The FDA Revitalization Act. Available online at: http://rpc.senate.gov/_files/L13S1082FDARevitalizationAct043007KP.pdf (accessed 30 October 2007).
78 Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD 28 monoclonal antibody TGN 1412. N Engl J Med. 2006; 355: 1018–28.
79 Lenzer J, Brownlee S. An untold story? BMJ. 2008; 336: 532–4.
80 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
81 Danish Medicines Agency. [Danish Medicines Agency’s Performance Contract 2007 –2010]. Available online at: www.laegemiddelstyrelsen.dk/db/filarkiv/6653/resultatkontrakt2007_2010.pdf (accessed 15 August 2008).
82 Okie S. Safety in numbers – monitoring risk in approved drugs. N Engl J Med. 2005;
352: 1173–6.
83 Carlsen LT. [A difficult balance]. Tænk + Test. 2003; 32: 30–3.
84 Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
85 Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516–27.
86 Woloshin S, Schwartz LM, Welch HG. Know your Chances: understanding health statistics. Berkely: University of California Press; 2008.
87 Woloshin S, Schwartz LM. Think inside the box. New York Times. 2011 July 4. 88 Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug
companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
89 Brennan TA, Rothman DJ, Blank L et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295: 429–33.
90 Tougaard H, Hundevadt K. [The golden promises of the gynaecologists].
Jyllandsposten. 2004 Jan 18.
91 Fugh-Berman A, McDonald CP, Bell AM, et al. Promotional tone in reviews of menopausal hormone therapy after the women’s health initiative: an analysis of published articles. PLoS Med. 2011; 8: e1000425.
92 Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 Aug 4.
93 Rosenberg M. Pfizer’s ghostwritten journal articles are still standing, still bogus.
Online Journal. 2010 Feb 23.
94 Gøtzsche PC. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
95 Conflicts of interest in biomedical research. Canada’s Voice for Academics. 2003; 50: Feb.
96 Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
97 Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
98 Bindslev JB, Schroll J, Gøtzsche PC, et al. Underreporting of conflicts of interest in clinical practice guidelines: cross-sectional study. BMC Med Ethics. 2013; 14: 19.
99 Steinbrook R. Controlling conflict of interest – proposals from the Institute of Medicine. N Engl J Med. 2009; 360: 2160–3.
100 Zinner DE, Bolcic-Jankovic D, Clarridge B, et al. Participation of academic scientists in relationships with industry. Health Aff. 2009; 28: 1814–25.
101 Lenzer J. French guidelines are pulled over potential bias among authors. BMJ.
2011; 342: d4007.
102 Clinard MB, Yeager PC. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
103 Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26. Available online at: www.reuters.com/article/2010/03/26/pharmaceutical-mergers- idUSN2612865020100326 (accessed 17 June 2012).
104 Wikipedia. List of countries by GDP (nominal). Available online at: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) (accessed 30 June 2012).
105 Annas GJ. Corporations, profits, and public health. Lancet. 2010; 376: 583–4.
106 Thomas K, Schmidt MS. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.
107 Khan H, Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case.
ABC News. 2010 April 27.
108 Brynner R, Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
109 House of Commons Health Committee. The Influence of the Pharmaceutical Industry.
Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
110 Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA. 2000; 283: 373–80.
111 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
112 Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
113 Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003; 290: 252–5.
114 Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324: 886–91.
115 Campbell EG. Doctors and drug companies: scrutinizing influential relationships. N Engl J Med. 2007; 357: 1796–7.
116 Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am JMed. 2001; 110: 551–7.
117 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry.
Lanham: Rowman & Littlefield; 2008.
118 Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742–50.
119 Lenzer J. Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011; 342: d2929.
120 Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. JAMA. 2007; 298: 1779–86.
121 Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4. 122 Steinbrook R. Physician-industry relations – will fewer gifts make a difference? N
Engl J Med. 2009; 360: 557–9.
123 Roehr B. US Institute of Medicine report calls for an end to firms’ drug and device promotion to doctors. BMJ. 2009; 338: 1100.
124 Steinman MA, Landefeld CS, Baron RB. Industry support of CME – are we at the tipping point? N Engl J Med. 2012; 366: 1069–71.
125 Norris SL, Holmer HK, Ogden LA, et al. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study. BMC Medical Ethics. 2012; 13: 24.
126 Arnfred CE, Pedersen LN, Agger C. [Politicians feel cheated by lobby-doctors].
Jyllandsposten. 2011 Aug 29.
127 Thirstrup S. [Can you sell diseases]? Rationel Farmakoterapi. 2010 Dec.
128 Borg O. [Pill ads are distributed in school yards]. Jyllands-Posten. 2011 Nov 1. 129 Herxheimer A. Relationships between the pharmaceutical industry and patients’
organisations. BMJ. 2003; 326: 1208–10.
130 Rathje M. [Heart Association scares the Danes]. TV2 News. 2012 April 20.
131 Cassidy J. The International Alliance of Patients’ Organizations. BMJ. 2011; 342: d3485.
132 [Danish Association of the Pharmaceutical Industry’s collaboration with patient associations and others in 2010]. 2010. Available online at: www.lifdk.dk/graphics/Lif/Inside%20Lif/2011/09/Medlemmers%20samarbejde%20m (accessed 28 June 2011).
133 Wolfe S. The seven-year rule for safer prescribing. Aust Prescr. 2012; 35: 138–9. 134 Jelinek GA, Brown AF. A stand against drug company advertising. Emergency
Medicine Australasia. 2011; 23: 4–6.
135 Altman DG. The scandal of poor medical research: we need less research, better research, and research done for the right reasons. BMJ. 1994; 308: 283–4.
136 Lexchin J, Light DW. Commercial influence and the content of medical journals.BMJ. 2006; 332: 1444–7.
137 Lundh A, Barbateskovic M, Hróbjartsson A, et al. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010; 7: e1000354.
138 Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1: e6.
139 Clinical knowledge: from access to action. Lancet. 2008; 371: 785.
140 Schwartz L, Woloshin S, Moynihan R. Who’s watching the watchdogs? BMJ. 2008;337: a2535.
22
References
1 Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008; 3: CD000193.
2 Frankfurt H. On Bullshit. Princeton, NJ: Princeton University Press; 2005. 3 Godlee F. Editor’s choice: say no to the free lunch. BMJ. 2005 Apr 16.
4 Fugh-Berman A. Doctors must not be lapdogs to drug firms. BMJ. 2006; 333: 1027.
5 Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
6 Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781.
7 Andersen NV. [Gunnar Lose vs. Yamanouchi]. Ugeskr Læger. 2006; 168: 546–9.
8 Andersen NV. [Gunnar Lose considers the committee on scientific dishonesty]. Ugeskr Læger. 2006; 168: 719–21.
9 Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48: 464–70.
10 Jonas U, Rackley RR. Eur Urol. 2006; 49: 187–8; author reply 188–90.
11 Rasmussen LI. [Danes suffer from 12 million diseases]. Ugeskr Læger. 2011; 173:
1767.
12 Andersen NV. [The drug industry increases lobbyism]. Mandag Morgen. 2007 Sep 3: 20–3.
13 Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10:CD009009.
14 Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, et al. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ. 2012; 345: e7191.
15 Lifestyle intervention in a general population for prevention of ischaemic heart disease. Study record. Available online at: http://clinicaltrials.gov/ct2/results? term=inter99&Search=Search (accessed 3 June 2013).
16 Kvist J. [The possibility of suicide]. Berlingske Tidende. 2002 Nov 3.
17 Getz L, Sigurdsson JA, Hetlevik I, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ. 2005; 331: 551.
18 Getz L, Kirkengen AL, Hetlevik I, et al. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care. 2004; 22: 202–8.
19 Alonso-Coello P, García-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008; 336: 126–9.
20 Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
21 Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535–41.
22 Erviti J. Bisphosphonates: do they prevent or cause bone fractures? Drug and Therapeutics Bulletin of Navarre. 2009; 17: 65–75.
23 Erviti J, Alonso Á, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case- control study. BMJ Open. 2013; 3: e002091.
24 Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95: 5258–65.
25 Moynihan R, Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
26 Montori VM, Isley WL, Guyatt GH.Waking up from the DREAM of preventing diabetes with drugs. BMJ. 2007; 334: 882–4.
27 Coombes R. Having the last laugh at big pharma. BMJ. 2007; 334: 396–7.
28 HAVIDOL: female testimonial. Available online at: www.youtube.com/watch? v=sQw_cdhXGco.
29 A new epidemic (motivational deficiency disorder). Available online at: www.youtube.com/watch?v=RoppJOtRLe4.
30 Moynihan R. Scientists find new disease: motivational deficiency disorder. BMJ 2006;332: 745.
31 Whitehead S. Fashionable to criticise the drug industry? BMJ. 2012; 345: e7089.
32 Gøtzsche PC. Lecture. Efficacité et effets indésirables des produits de santé: données confidentielles ou d’intérêt public? Available online at: www.prescrire.org/Docu/Archive/docus/PiluledOr2013_Conf_Gotzsche.pdf (accessed 8Feb 2013).
Leave a Comment